

# STEPHEN H. MASON, MD

Curriculum Vitae

3633 Central Ave. Ste N  
Hot Springs, AR 71913

Telephone: (501)623-6100

---

## PERSONAL

**DOB:** June 29, 1971      **Place of Birth:** Midland, TX, US Citizen  
**Sex:** Male      **Marital Status:** Married to Sharron Mason, MD  
**Race:** Caucasian      **Children:** Siobahn Bower, MD and Amanda Shepherd

## EDUCATION

**Texas Tech University School of Medicine, Lubbock/Amarillo, TX**

Doctor of Medicine, *May 1998*

**Baylor University, Waco, TX**

Master of Clinical Gerontology, *August 1994*

**Baylor University, Waco, TX**

Bachelor of Arts in Biology, *May 1993*

## TRAINING

**Texas Tech Health Sciences Center School of Medicine, Lubbock, Texas**

Internal Medicine Preliminary Internship, *July 1998-June 1999*

**Louisiana State University Medical Center-Shreveport, Louisiana**

Dermatology Clinical Research Fellowship, *July 1999-June 2000*

**Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts**

Dermatology Clinical Research Fellowship, *July 2000-June 2001*

**Tulane University Medical Center, New Orleans, Louisiana**

Dermatology Clinical Research Fellowship, *July 2001-June 2002*

Dermatology Resident, *July 2001-June 2005*

**City of New Orleans/Delgado Sexually Transmitted Disease Clinic, New Orleans, Louisiana**

Staff Clinician, *July 2001-June 2003*

**Louisiana State University Medical Center-New Orleans, Louisiana**

Mohs Micrographic Surgery Fellow, *July 2005-August 2005 (60 day break due to Hurricane Katrina)*

**Baylor College of Medicine, Houston, Texas**

Procedural Dermatology and Mohs Surgery Fellow, *October 25, 2005-June 2006*

## BOARD CERTIFICATION

**American Board of Dermatology, October 2005**

## EMPLOYMENT

**University of Kansas Medical Center, Kansas City, Kansas**

Assistant Professor and Director of Dermatologic and Mohs Surgery, *July 2006-June 2007*

**Medical College of Georgia, Augusta, Georgia**

Assistant Professor and Director of Dermatologic and Mohs Surgery, *July 2007-March 2008*

**The Georgia Center for Dermatology, Evans, Georgia**

Mohs Surgery and General Dermatology, *April 2008-September 2008*

**The Dermatology Clinic, Hot Springs, Arkansas**

General Dermatology and Mohs Surgery, *December 2008-Present*

## AWARDS and HONORS

Medical School Class President 1995-1998

President of Medical Student Government, 1995-96

Member Aging and Long-Term Care Committee, Texas Medical Association, 1996-1998

*Winner* of the Werner-Hatchett award for Humanities in Medicine for "Human Ties" Poetry Collection. April 24, 1998

*Winner* Peterkin Award for Research for LSU and Tulane Senior Resident Research Projects, "Black Box Warning", Directly

Measuring Sunscreen and Topical Retinoid Use in Subjects Viewing Self UV Reflectance Photography at Variable Intervals June 5, 2005

## PROFESSIONAL SOCIETY MEMBERSHIPS

American Academy of Dermatology, Fellow

American College of Mohs Surgery, Associate

American Society of Dermatologic Surgeons, Fellow

Skin Cancer Foundation

Women's Dermatologic Society  
Georgia Society of Dermatologists

## **PUBLICATIONS**

*Tonkovic-Capin M, Aries DJ, Mason SH, Tonkovic-Capin V.* Practical Checklists for Common Cosmetic Procedures Performed at the Kansas University Medical Center Dermatology Clinic. *Cosmetic Dermatol.* (In Press)  
*Steyadi HG, Cohen PR, Schultze KE, Mason SH, Martininelli PT, Alford EL, Taffet GE, Nelson BR.* Self-Induced Nasal Ulceration: Trigeminal Trophic Syndrome. *J Southern Med Assn.* 100(1):43-48, January 2007.  
*Rapini RP, Mason SH,* Cutaneous Cytomegalovirus. (In Progress)  
*Glashofer M, Coleman WP, Lewis A, Mason SH, Plaisance, J.* Seroma Formation Following Abdominal Liposuction, *J Dermatol Surg.* 2005;31(7);770  
*Mason SH, Rapini RP:* Cutaneous Cytomegalovirus. *Cutis.* (in progress)  
*Mason SH, Cohen PR:* Vitiligo. *J Greater Houston Dental Soc* 1998;69(7);12-3  
*Mason SH;* Human Ties, A collection of poems on my experiences in the hospital and clinic as a medical student.

## **BOOK CHAPTERS**

*Doherty, S, Mason SH, Jacobs A, Orengo I.* Rhombic Flaps, Byrnes Atlas Facial Plastic and Reconstructive Surg. (In Press)  
*Setyadi, H, Mason SH, Orengo I.* Skin Neoplasms in the Elderly, *Clin in Dermatol.* 2006 (In Press)  
*Mason SH, Hogan D:* Sebaceous Hyperplasia, in James WR, et al: *Emedicine Dermatology*, St Petersburg, Emedicine Corporation, 2000  
*Mason SH, Hogan D:* Pityrosporum Folliculitis, in James WR, et al: *Emedicine Dermatology*, St Petersburg, Emedicine Corporation, 2000  
*Mason SH, Hogan D:* Prurigo Nodularis, in James WR, et al: *Emedicine Dermatology*, St Petersburg, Emedicine Corporation, 2000  
*Mason SH, Hogan D:* Lichen Simplex Chronicus, in James WR, et al: *Emedicine Dermatology*, St Petersburg, Emedicine Corporation, 2000

## **ACADEMIC LECTURES**

"Dermatologic Surgery" Family Practice Conference, KU Medical Center, February 21, 2007  
"Mohs Micrographic Surgery" Internal Medicine Grand Rounds, KU Medical Center, March 7, 2007  
"Why Skin? Organ Transplant Patient Pre-op Evaluation, Education and Surveillance" Internal Medicine Research Conference, Medical College of Georgia, September 16, 2007  
"Update on Skin Cancer" University Hospital CME, Augusta, GA April 10, 2007  
"Mohs Surgery and Horizontal Frozen Sections" MCG Pathology Symposium, Augusta, GA April, 19, 2007  
"Common Benign Skin Neoplasms" University Hospital CME, Augusta, GA September 4, 2008

## **RESEARCH AFFILIATION**

**Burke Pharmaceutical Research** – 3633 Central Avenue, Ste. I Hot Springs, AR 71913  
December 2008 - present

## **PROFESSIONAL INTERESTS**

Skin Cancer and Skin Surgery, Mohs Technique, Transplant Skin Surveillance, UVA-Reflectance Photography

## **PERSONAL INTERESTS**

Saxophone, Fishing, Table Tennis, Writing Poetry, Herb Gardening, Escaping Hurricanes

## **CLINICAL RESEARCH**

### **at LSU Shreveport Division of Dermatology**

1999 Novartis---Sub-Investigator

A randomized, double blind, parallel group study to determine the effective duration (1,2,or 4 weeks) and safety of Lamisil (tablets) given once daily to patients with tinea capitis due to trichophyton species (mainly T. TONSURANS) csf0327 t201:phase 2b

1999 Collaborative project with Texas Tech Dept. of Dermatology---Sub-Investigator  
Investigation of a Human Herpes Virus 7 as a Causative Agent for Pityriasis Rosea.

### **at Harvard Department of Dermatology Clinical Investigations Unit**

2001 Novartis---Sub-Investigator

A Randomized, Double-Blind, Multi-Center Study of the Blood Concentrations, Safety and Efficacy of 1% SDZ ASM 981 Cream Administered up to Four Times Daily in Adolescents and Adults with Atopic Dermatitis

2001 Novartis—Sub-Investigator

A 12 week, randomized, multicenter, double-blind, placebo-controlled study to determine the dose response, safety and tolerability of three doses (10, 20, 30 mg b.i.d.) of SDZ ASM 981 tablets in adult

2000-CoPharma---Sub-Investigator

A Phase I/II Study of the Safety and Efficacy of PEN203 in the Treatment of Superficial and Nodular Basal Cell Carcinoma of the Skin

2000-CoPharma---Sub-Investigator

A phase I/II study of the Safety and Efficacy of PEN203 in the Treatment of External Genital Warts in Males

2000-3M Pharmaceuticals---Sub-Investigator

A Phase III Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the treatment of Superficial Basal Cell Carcinoma

2000-Biogen, Inc---Sub-Investigator

A Randomized, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Evaluate the Safety of Intramuscular Administration of LFA3TIP (LFA-3/IgG1 Fusion Protein) in Subjects with Chronic Plaque Psoriasis

2000-Galderma---Sub-Investigator

A Dose Determination Study Comparing Two Different Concentrations of Nadifloxacin Cream to its Vehicle Twice Daily in the Treatment of Subjects with Acne Vulgaris

2000-Presutti Labs---Sub-Investigator

Topical Cromolyn for Epidermal Pruritus due to Lichen Simplex Chronicus or Idiopathic Senile Pruritus

2000-Genentech, Inc.---Sub-Investigator

A Phase III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter, Multidose Study to Evaluate the Efficacy and Safety of Subcutaneously Administered Anti-CD11a in Adults with Moderate to Severe Plaque Psoriasis

2000-Novartis Pharmaceuticals, Inc.---Sub-Investigator

A 3-Week Randomized, Multicenter, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of 1% SDZ ASM 981 Cream in Subjects with Chronic Hand Dermatitis, Followed by a 23-Week Open Label Phase to Assess Long-Term Safety of 1% SDZ ASM 981 Cream

- 1999-Fujisawa Healthcare---Sub-Investigator  
An Open-Label Study to Evaluate the Safety of Topically Applied Tacrolimus Ointment for the Treatment of Atopic Dermatitis
- 1999-Novartis Pharmaceuticals---Sub-Investigator  
A 26-Week Study with a 6-Week Randomized, Multicenter, Double-Blind, Vehicle-Controlled, Parallel-Group Phase Followed by a 20-Week Open-Label Phase to Study the Safety and Efficacy of 1% ASM Cream in Pediatric Patients with Atopic Dermatitis

**at Tulane Department of Dermatology Clinical Research Unit**

- 2001-Bailer/Altana---Sub-Investigator  
A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Determine the Therapeutic Equivalence of Two Ciclopirox Olamine 1% Formulations in the Treatment of Interdigital Tinea Pedis
- 2001-Galderma---Sub-Investigator  
A Randomized, Double-Blind, Parallel Group Evaluation of Clobetasol Propionate Shampoo, 0.05% Versus Its Vehicle—An Efficacy and Safety Study in Subjects With Scalp Psoriasis
- 2001—Galderma---Sub-Investigator  
Long-Term Safety Assessment of Helioblock SX Cream in Patients with Polymorphous Light Eruption
- 2001-Allergan---Sub-Investigator  
A Multicenter, Open-Label Safety Study of Tazarotene 4.5 mg Capsules Once Daily in Patients with Moderate to Very Severe Psoriasis Treated for up to One Year Followed by a 12-Week Post-Treatment Follow-up Period
- 2001—Watson Laboratories---Sub-Investigator  
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Fluconazole Topical Patch in the Treatment of Distal Subungual Onychomycosis of the Great Toenail
- 2001—Ligand Pharmaceuticals/Millennix, Inc.---Sub-Investigator  
A Multicenter, Dose-Randomized Evaluation of Targretin Capsules + PUVA in Patients with Stage IB-IIA Cutaneous T-Cell Lymphoma
- 2002---Novartis/PPD Development---Sub-Investigator  
A 6 Month, Randomized, Multicenter, Parallel Group, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of ASM 981 (Pimecrolimus) 1% BID versus Standard of Care in the Management of Mild to Severe Atopic Dermatitis in Adults
- 2005—Mason SH, Investigator  
Phase IV, Subject-blinded Pilot Study Measuring Rates of Use of MD Forte SPF 30 Sunblock and Tazorac 0.1% Gel After Viewing Photos from \$50 UV Reflectance Photography Unit.

**at University of Kansas Medical Center**

- 2007 –KUMC Surgical Oncology—Sub Investigator  
Pilot Study Evaluating The Sensitivity and Specificity of Positron Emission Tomography with Computed Tomography (PET/CT) Scanning in the Detection of Nonpalpable Metastatic Disease in Axial T3 or T4 Cutaneous Malignant Melanoma.

**at Burke Pharmaceutical Research**

- 2009 – The GlaxoSmithKline group of companies—Sub Investigator  
A randomized, Double-Blind, placebo-and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of XXXX Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and With Metformin Plus Glimepiride and Pioglitazone in Subjects with type 2 diabetes mellitus. Subjects with Type 2 Diabetes Mellitus
- 2009 – Taro Pharmaceuticals USA, Inc—Sub Investigator  
A multi-center Phase III Study to Evaluate MALG, a Novel XXX Formulation, for the Control of Head Lice in Pediatric Subjects and Adult Subjects with Pediculosis capitis
- 2009—Galderma Laboratories, L.P. – Principal Investigator  
A Phas 4, Open- Label, Multicenter, Community-based, 12-Week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction With XXXX When Used as Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of Rosacea
- 2009—TOLMAR Inc.—Sub Investigator  
A Double-Blind, Randomized Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of XXXXXXXX and XXXXX Gel, 3% and Compare Both Active Treatments to a Vehicle Control in the Treatment of Actinic Keratosis
- 2009—Galderma—Principal Investigator  
A Four-Week, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of XXXXX Ointment 3cg/g Twice Daily in the Treatment of Adults with at Least Moderate Atopic Dermatitis
- 2009---Schering Plough ---Principle---Investigator Supplemental Self-Selection/Self-Diagnosis Study for Over-the-Counter (OTC) Skin Tag Remover
- 2009---Peplin----Sub-Investigator---A multicenter, randomized, parallel group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of XXXX in patients with actinic keratoses on non-head locations
- 2009—Peplin---Sub-Investigator--- A multi-center, Randomized, parallel group, double-blind, vehicle-controlled study to evaluate the Efficacy and safety of XXXXX In patients with actinic keratoses ON the head (face or scalp)
- 2009---Galderma---Sub-Investigator--Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Dose-Finding Study Investigating the Pharmacodynamics and Safety of Three Concentrations of XXXXX Topical Gel (0.07%, 0.18%, and 0.50%), Applied in Subjects with Moderate to Severe Erythematotelangiectatic Rosacea